Core Viewpoint - The AI Fund, Rongtong Xinxin Growth Mixed A, reported a profit of 35.4486 million yuan for Q2 2025, with a net value growth rate of 12.82% and a fund size of 400 million yuan as of the end of Q2 2025 [2][15]. Fund Performance - As of July 17, 2025, the fund's one-year cumulative net value growth rate was 48.74%, ranking 50 out of 133 comparable funds [3]. - The fund's three-month net value growth rate was 21.94%, ranking 84 out of 138 comparable funds, while the six-month growth rate was 29.74%, ranking 86 out of 138 [3]. - The fund's three-year Sharpe ratio was 0.4914, ranking 12 out of 105 comparable funds [8]. Investment Strategy - The fund adheres to a contrarian investment style, focusing on sectors and stocks with good growth potential and relatively low valuations, while adjusting the portfolio structure as needed [2]. - The investment direction emphasizes domestic demand and technology, with a focus on opportunities arising from China's economic transformation and recovery [2]. - The fund is optimistic about investment opportunities in the pharmaceutical sector, particularly in the context of aging demographics, as well as in innovative drugs and high-end manufacturing with global competitive advantages [2]. Portfolio Composition - As of June 30, 2025, the fund's average stock position over the past three years was 92.67%, with a peak of 94.34% at the end of H1 2025 [13]. - The top ten holdings of the fund include companies such as Aibo Medical, Gushengtang, and Sanyou Medical, indicating a strong focus on the healthcare sector [18]. Risk Metrics - The fund's maximum drawdown over the past three years was 38.36%, ranking 59 out of 105 comparable funds, with the largest single-quarter drawdown occurring in Q1 2024 at 27.81% [10].
融通鑫新成长混合A：2025年第二季度利润3544.86万元 净值增长率12.82%
Sou Hu Cai Jing·2025-07-18 03:03